Extended Data Fig. 5: Immune cell accumulation in mesenteric lymph fluid and lymph nodes across prevention and treatment groups.
a-b, Total immune cells in mesenteric lymph fluid and lymph nodes. Mean ± s.e.m., (a) n = 5, 4 (week 6), n = 8, 9 (week 15), n = 6, 6 (week 32). (b) n = 5, 5 (week 6), n = 5, 5 (week 15), n = 6, 6 (week 32). c, Percent of CD45 + cells that were T cells (CD3 + ), B cells (CD19 + ), dendritic cells (CD11c + ), macrophages (F4/80 + ) and NK cells (NK1.1), and d, Percent of T cells that were Th1 (IFNγ + ), Th2 (IL-4 + ) and Th17 (IL-17 + ) cells in mesenteric lymph nodes of mice fed CFD or HFD for 6, 15 or 32 weeks. (c-d) all data at week 15 with n = 5 (CFD), 7 (HFD, except n = 5 for CD11c + and NK1.1+ cells). e, f, Total immune cells in mesenteric lymph fluid or node of mice fed with CFD, HFD or HFD plus Celecoxib (Cele) for 15 weeks (prevention study, see timeline Fig. 4e). Mean ± s.e.m., (e) n = 5, 5, 4. (f) n = 9, 10, 7. g-h, Percent of CD45 + cells that were T cells (CD3 + ), B cells (CD19 + ), dendritic cells (CD11c + ), macrophages (F4/80 + ) and NK cells (NK1.1) in mesenteric lymph fluid or nodes of mice fed with CFD, HFD or HFD plus celecoxib or Cele-Pro (treatment study, see timeline Fig. 5a). Mean ± s.e.m., (g) n = 6, 7, 4, 5 and (h) n = 5, 7, 6, 5 (except n = 4 for CFD NK1.1+ cells, n = 6 for HFD CD3 + cells and n = 6 HFD NK1.1+ cells). Statistical differences from two-tailed Student’s t-test (a-d) or one-way ANOVA (e-h), *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. P values and details of the statistical testing are provided as source data.
